Dwight Akerman

Featured in: Favicon

reviewob.com Favicon

reviewofmm.com Favicon

visionyoptica.com

Articles

2024: A Remarkable Year for Myopia Management

Jan 2, 2025 | reviewofmm.com | Dwight Akerman

January 2, 2025By Dwight Akerman, OD, MBA, FAAO, Dipl AAO, FBCLA, FIACLEJuvenile-onset myopia has gained the scientific community’s attention, and 2024 was a stellar year for myopia publications. According to PubMed, over 2,500 papers on various aspects of myopia, childhood myopia, myopia management, and myopia control have been published globally in peer-reviewed literature during 2024.
Multifocal Soft Contact Lenses for the Treatment of Myopia Progression in Children

Jan 1, 2025 | reviewofmm.com | Dwight Akerman

January 2, 2025By Dwight Akerman, OD, MBA, FAAO, Dipl AAO, FBCLA, FIACLEThe American Academy of Ophthalmology prepares Ophthalmic Technology Assessments to evaluate new and existing procedures, drugs, and diagnostic and screening tests. The goal of an Ophthalmic Technology Assessment is to systematically review the available research for clinical efficacy, effectiveness, and safety.
Review of Myopia Management

Dec 16, 2024 | reviewofmm.com | Dwight Akerman

December 16, 2024By Dwight Akerman, OD, MBA, FAAO, Dipl. AAO, FBCLA, FIACLEThe study by Brennan, Cheng, and Bullimore (2024) investigates the progression of myopia in adults aged 20 to 50. The research addresses an important aspect of ocular health, particularly the increasing prevalence of myopia and its potential implications for visual impairment.
Working Toward an Approved Pharmacological Treatment for Myopia Management

Dec 16, 2024 | reviewofmm.com | Dwight Akerman

sponsored contentDecember 16, 2024Privately held, clinical-stage pharmaceutical company, Sydnexis Inc. has recently completed an evaluation of its patented low-dose atropine formulation, SYD-101, in a Pivotal Phase 3 clinical trial. Based in San Diego and founded in 2014, Sydnexis recently named Perry J. Sternberg Chief Executive Officer.
Myopia is a Disease. Period.

Nov 1, 2024 | reviewofmm.com | Dwight Akerman

November 1, 2024By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLEMyopia is not just a simple vision problem, disorder, or condition — it’s a disease that is becoming more common worldwide. According to the World Health Organization (WHO), a disease is “any harmful deviation from the normal structural or functional state of an organism, generally associated with certain signs and symptoms and differing in nature from physical injury.
Review of Myopia Management

Nov 1, 2024 | reviewofmm.com | Dwight Akerman

November 1, 2024Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLEIn their review article, “Efficacy in myopia control — The impact of rebound,” Bullimore and Brennan explore the phenomenon of rebound effect after the discontinuation of myopia control treatment. The authors aim to investigate whether myopia progression, after the cessation of treatment, reverts to expected values based on the age and race of the child, or if it accelerates further, which is termed as a rebound.
Childhood Myopia and Dry Eye: Are They Related?

Nov 1, 2024 | reviewofmm.com | Dwight Akerman

November 1, 2024By James S.
CooperVision Announces Student Myopia Leadership Society Members

Oct 31, 2024 | reviewofmm.com | Dwight Akerman |Kristen Dalli

October 31, 2024SAN RAMON, Calif. — The CooperVision Student Myopia Leadership Society members for 2024-2025 have officially been announced. The Student Myopia Leadership Society provides educational experiences for a student at each school and college of optometry in North America who is dedicated to helping treat children with myopia. The student will learn more about the evolving landscape of myopia management and how to achieve the best evidence-based outcomes in clinical practice.
Topcon Partners with Ocumetra for Myopia Management Advancements

Oct 31, 2024 | reviewofmm.com | Dwight Akerman |Kristen Dalli

October 31, 2024DUBLIN, Ireland — Ocumetra has announced an investment and partnership with Topcon Healthcare, Inc. to further advance myopia management outcomes for children. This collaboration combines Ocumetra’s myopia management platform with Topcon Healthcare’s cloud-based Harmony digital health platform to ensure eye care providers can access and utilize myopia clinical support solutions at scale.
VTI’s Chief Medical Officer Dr. Ashley Tuan Shares PROTECT Study Data at IMC

Oct 15, 2024 | reviewofmm.com | Aaron Wolf |Dwight Akerman |Kristen Dalli

sponsored contentOctober 15, 2024SANYA, Hainan Island, China – Dr. Ashley Tuan, OD, PhD, the Chief Medical Officer of Visioneering Technologies, Inc. presented a poster at this year’s International Myopia Conference about the PROTECT study’s one-year interim analysis. In this video, Dr. Tuan shares some more advanced analysis of the study results. In addition, Dr. Tuan explains “adjusted” results vs. “unadjusted” results in studies such as this one and why the difference between them matters.